A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS ISSN： 0393-6155 出版频率： Quarterly 出版社： WICHTIG EDITORE, 72/74 VIA FRIULI, MILAN, ITALY, 20135   出版社网址： http://www.wichtig-publisher.com/ 期刊网址： http://www.biological-markers.com/index.asp?a=current 影响因子： 1.265(2008) 主题范畴： BIOTECHNOLOGY & APPLIED MICROBIOLOGY;    ONCOLOGY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal THE INTERNATIONAL JOURNAL of BIOLOGICAL MARKERS publishes original contributions, editorials and current reviews dealing with basic and applied research in the field of tumor markers. The Journal accepts contributions on the following topics which are at present a rapidly growing field of basic and clinical research: CIRCULATING TUMOR MARKERS They include all those substances secreted by cancer cells or produced by the host as a reaction against the tumor, which can be an index of tumor growth. CELLULAR TUMOR MARKERS They include all nuclear, cytoplasmatic or membrane markers studied by means of histological or cytological investigations or molecular biology techniques, that can detect any difference between normal and cancer cells. CELL PROLIFERATION MARKERS They include all markers related to cell proliferation, studied by means of autoradiographic, flow cytometric or immunohistochemical approaches, which can characterize normal and cancer cells. HORMONE AND GROWTH FACTOR RECEPTORS The study of hormone and growth factor receptors as biological markers of cancer is an attempt to correlate the presence of these physiological agents of cell regulation with the natural history of the neoplasia and other prognostic factors. RADIOIMMUNODETECTION This is the application in vivo of the antibodies used in vitro to detect circulating tumor markers or cellular markers. The development of immunoscintigraphy originates from the basic research ot tumor markers and can be employed as a possible approach for the diagnosis of cancer. IMMUNOTHERAPY This field includes the therapeutical utilization of the same antibodies studied in experimental models and in the clinical application of immunoscintigraphy. By labelling the antibodies with radioisotopes or with drugs it is possible to use them as antitumor agents. All these topics are actively investigated today in their basic aspects and new reagents and technologies of cancer detection are being perfected. Their application in clinical practice allows a critical evaluation of the importance and the usefulness of this research. For these reasons, the subjects should be considered a very interesting area of discussion and development. Instructions to Authors Manuscripts should be submitted DIRECTLY to the Editorial office: Dr Massimo Gion, Centro Nazionaleper l'Applicazione delle Biotecnologie in Oncologia Ospedale Civile 30122 Venezia (Italy) Phone +39 041 5294535 - Fax +39 041 5294653 E-mail: cnabo@provincia.venezia.it Three sets of figures and illustrations must be enclosed. All manuscripts will be read by the Editor(s) and reviewed further by two reviewers. The Editors reserve the right to make corrections in grammar and style. Form and contents should be very carefully checked to exclude the need for later corrections. Galley proofs must be sent back within 48 hours from receipt, otherwise they will be corrected by the publisher. The approximate positions of figures and tables must be marked in the margin. Authors may purchase reprints at prices furnished with the letter of acceptance. The senior author of each article will receive a complimentary copy of the issue containing his article. The International Journal of Biological Markers publishes full papers, review articles, short communications and letters to the editor. Manuscript categories Full papers These should concern the results of clinical or biological studies based on sound patient series, validated analytical methods and appropriate statistical evaluation. The typical length is 3000-4000 words (not including tables, figures and references); the abstract should not exceed 200 words. Manuscripts should include the following sections: Abstract, Introduction, Materials and methods, Results, Discussion and References. Short communications These should report preliminary data of ongoing studies or marginal findings that may be of interest to a limited audience. Typical length 1500-2500 words. A limited number of tables and/or figures (not more than 4 in total) and not more than 20 references may be included. Short communications should be subdivided into sections as full papers. Letters to the editor The typical length is 750-1000 words, including one figure or table and not more than 10 references. Review articles Systematic critical assessments of published data concerning biomarkers and their clinical use are appreciated. The methodology used for the search of source material, the selection of literature and the attribution of levels of evidence to conclusions or recommendations should be carefully explained. Meta-analyses will also be considered as reviews. Review articles should include headings that are appropriate to the text. Manuscript organization The Journal adopts the Vancouver style with the uniform requirements for manuscripts submitted to biomedical journals as modified at the meeting of October, 1981. Type the manuscript on white bond paper, 203 x 267 mm or 216 x 279 mm (8x10.5 in or 8.5x11 in) or ISO A4 (212 x 297mm) with margins of at least 2.5 cm (1 in). Use double spacing and begin each of the following sections on separate pages: title page, abstract and key words, text, acknowledgements, references, individual tables, and legends. Number pages consecutively, beginning with the title page. Type the page number in the upper right-hand corner of each page. Manuscripts will be reviewed for possible publication with the understanding that they are being submitted to one journal at a time and have not been published, simultaneously submitted, or already accepted for publication elsewhere. This does not preclude consideration of a manuscript that has been rejected by another journal or of a complete report that follows publication of preliminary findings elsewhere, usually in the form of an abstract. Copies of any possibly duplicative published material should be submitted with the manuscript that is being sent for consideration. Title page The title page should contain (1) the title of the article; (2) a short running head of no more than 40 characters (count letters and spaces); (3) first name, middle initial, and last name of each author; (4) name of department(s) and institution(s) to which the work should be attributed; (5) name and address of author responsible for correspondence about the manuscript; (6) the source(s) of support in the form of grants, equipment, drugs, or all of these. Abstract and key words The second page should carry an abstract of not more than 200 words. The abstract should state the purposes of the study or investigation, basic procedures, main findings, and the principal conclusions. Key (indexing) terms - Below the abstract, provide and identify as such, three to ten key words that will assist indexers in cross- indexing your article. Abbreviations The Journal accepts standard abbreviations indi-cated by the Journal of Biological Chemistry and by the IUPAC (International Union of Pure and Applied Chemistry). All non-standard abbreviations should be defined in parentheses when they first appear in text. In addition, they should be listed on the second page of the manuscript. Text The text of articles is usually divided into sections with the headings Introduction, Methods, Results, and Discussion. Long articles may need subheadings within some sections to clarify their content, especially the Results and Discussion sections. Other types of articles such as case reports, reviews, and editorials are likely to need other formats. When reporting experiments on human subjects, indicate whether the procedures followed were in accord with the ethical standards of the committee on human experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration. Do not use patients' names, initials, or hospital numbers. Use of the Syst鑝e International d'Unit閟 (Sl) for measurements is preferred throughout the manuscript. Acknowledgements Acknowledge only persons who have made substantive contributions to the study. Authors are responsible for obtaining written permission from everyone acknowledged by name because readers may infer their endorsement of the data and conclusions. References Number references consecutively in the order in which they are first mentioned in the text. Identify references in text, tables, and legends by Arabic numerals (in parentheses). References cited only in tables or in legends to figures should be numbered in accordance with a sequence established by the first identification in the text of the particular table or illustration. The titles of journals should be abbreviated according to the style used in Index Medicus (consult the "List of journals indexed", printed annually in the January issue of Index Medicus). Examples of correct forms of references are given below: 1. Standard journal article - (List all authors when six or less; when seven or more, list only first three and add et al.) You CH, Lee KY, Chey WY, Menguy R. Electrogastro-graphic study of patients with unexplained nausea, bloating and vomiting. Gastroenterology 1980; 79: 311-4. 2. Chapter in a book Weinstein L, Swarts MN. Pathogenic properties of invading microorganisms. In: Sodeman WA Jr, Sodeman WA, eds. Pathologic physiology: mechanisms of disease. Philadelphia: WB Saunders, 1974; 457-72. Tables Type each table on a separate sheet; remember to double space. Number tables consecutively using roman numerals and supply a brief title for each. Place explanatory matter in footnotes, not in headings. Cite each table in the text in consecutive order. Figures Figures should be accurately drawn. Pictures which do not satisfy the standard will not be accepted. Include three clear photocopies of figures with the original, each clearly labelled on the back. Cite each figure in the text in consecutive order. If a figure has been published, acknowledge the original source and submit written permission from the copyright holder to reproduce the material. Permission is required, regardless of authorship or publisher, except for documents in the public domain. Legends for figures Type legends for figures double spaced, starting on a separate page with Arabic numerals corresponding to the figures. When symbols, arrows, numbers, or letters are used to identify parts of the figures, identify and explain each one clearly in the legend. Submission of manuscripts Mail three copies of the manuscript in a heavy paper envelope, enclosing the manuscript copies and figures in cardboard, if necessary. Place photographs or figures in a separate heavy paper envelope. Manuscripts should be accompanied by a covering letter from the author who will be responsible for correspondence regarding the manuscript. The covering letter should contain a statement that the manuscript has been seen and approved by all authors. The letter should give any additional information that may be helpful to the editor. A 3.5 floppy disk containing the text written in an IBM compatible word processing format should be provided after final acceptance of the manuscript. Editorial Board Editor-in-Chief Massimo Gion Venezia Co-Editors Maria Grazia Daidone Milano Robin Leake Glasgow Associate Editors R. Blankenstein Utrecht E. Bombardieri Milano A. Carbone Aviano H. Fritsche Houston G. Gasparini Roma F. Guadagni Roma H. Magdel閚at Paris J.P. Peyrat Lille M. Plebani Padova M.K. Schwartz New York Editorial Board A. Albini Genova D. Amadori Forl?/td> A. Anichini Milano A.M. Ballesta Barcelona A. Becciolini Firenze F. Boccardo Genova J.M.G. Bonfrer Amsterdam P. Boracchi Milano G. Bussolati Torino G. Cappelli Firenze L. Castagnetta Palermo M. Castelli Roma D. Chan Baltimore S. Ciatto Firenze G.M. Clark San Antonio M. Correale Castellana (BA) A. Costa Milano G. Daxenbichler Innsbruck M. De Bortoli Candiolo (TO) E.P. Diamandis Toronto R. Dittadi Venezia M.J. Duffy Dublin A. Epenetos London M. Ferno Lund G. Francini Siena R. Giavazzi Bergamo D.M. Goldenberg Belleville W. J鋑er Erlangen R. Lamerz M黱chen A. Liberati Milano G. Madeddu Sassari S. M閚ard Milano R. Molina Barcelona S. Monfardini Padova P.G. Natali Roma A. Nicolucci S. Maria Imbaro, (CH) B. Nordenskjold Link鰌ing M. Nuti Roma C. Ortolani Venezia F. Pacini Pisa M. Paganuzzi Genova A. Paradiso Bari S. Pecorelli Bari M. Pierotti Milano A. Piffanelli Ferrara M.R. Price Nottingham M. Puente Madrid J.F.R. Robertson Nottingham A. Ruibal Morel Madrid J. Schlom Bethesda G. Secreto Milano E. Seregni Milano A.G. Siccardi Milano D.A. Spandidos Heraklion U.H. Stenman Helsinki P. Stieber M黱chen F. Sweep Nijmegen K. Taketa Ibara S.E. Taube Rockville M. Toi Tokyo G.C. Torre Pietra Ligure (SV) C.M. Tsiapalis Athens A. van Dalen Gouda S. von Kleist Freiburg G.C. Zucchelli Pisa Advisory Board C.R. Bast Jr. Houston F. Berrino Milano G. Bevilacqua Pisa N. Brunner Copenhagen G.L. Buraggi Milano E. V. Jensen Huddinge G. Mariani Pisa E. Marubini Milano M. Salvatore Napoli L. Santi Genova R. Silvestrini Milano U. Veronesi Milano